177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers

IF 9.6 1区医学 Q1 ONCOLOGY

Cancer treatment reviews Pub Date : 2024-02-17 DOI:10.1016/j.ctrv.2024.102699

Emilio Francesco Giunta , Nicole Brighi , Giorgia Gurioli , Federica Matteucci , Giovanni Paganelli , Ugo De Giorgi

{"title":"177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers","authors":"Emilio Francesco Giunta , Nicole Brighi , Giorgia Gurioli , Federica Matteucci , Giovanni Paganelli , Ugo De Giorgi","doi":"10.1016/j.ctrv.2024.102699","DOIUrl":null,"url":null,"abstract":"<div><p>177Lu-PSMA has been approved for the treatment of PSMA-positive metastatic castration-resistant (mCRPC) patients who progressed to androgen receptor pathway inhibitors (ARPIs) and taxane-based chemotherapy. However, a higher proportion of patients do not respond to this type of radioligand therapy (RLT). To date, there is a lack of validated prognostic and predictive biomarkers for 177Lu-PSMA therapy in prostate cancer. Several studies have investigated the prognostic and predictive role of clinical and molecular factors and also the metabolic features of PET imaging. In this review, we aim to take stock of the current scenario, focusing on new emerging data from retrospective/prospective series and clinical trials. Given the high costs and the possibility of primary resistance, it seems essential to identify clinical and molecular characteristics that could allow clinicians to choose the right patient to treat with 177Lu-PSMA. Biomarker-based clinical trials are urgently needed in this field.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":9.6000,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000173/pdfft?md5=160030d37532638066675fd576081b44&pid=1-s2.0-S0305737224000173-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0305737224000173","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

177Lu-PSMA has been approved for the treatment of PSMA-positive metastatic castration-resistant (mCRPC) patients who progressed to androgen receptor pathway inhibitors (ARPIs) and taxane-based chemotherapy. However, a higher proportion of patients do not respond to this type of radioligand therapy (RLT). To date, there is a lack of validated prognostic and predictive biomarkers for 177Lu-PSMA therapy in prostate cancer. Several studies have investigated the prognostic and predictive role of clinical and molecular factors and also the metabolic features of PET imaging. In this review, we aim to take stock of the current scenario, focusing on new emerging data from retrospective/prospective series and clinical trials. Given the high costs and the possibility of primary resistance, it seems essential to identify clinical and molecular characteristics that could allow clinicians to choose the right patient to treat with 177Lu-PSMA. Biomarker-based clinical trials are urgently needed in this field.

查看原文本刊更多论文

转移性前列腺癌的 177Lu-PSMA 治疗：预后和预测生物标志物的最新综述

177Lu-PSMA已被批准用于治疗对雄激素受体途径抑制剂（ARPI）和以类固醇为基础的化疗有进展的PSMA阳性转移性阉割耐药（mCRPC）患者。然而，较高比例的患者对这种放射性配体疗法（RLT）没有反应。迄今为止，前列腺癌的 177Lu-PSMA 治疗缺乏有效的预后和预测生物标志物。有几项研究调查了临床和分子因素的预后和预测作用，以及 PET 成像的代谢特征。在这篇综述中，我们旨在总结目前的情况，重点关注来自回顾性/前瞻性系列研究和临床试验的新数据。考虑到高昂的费用和原发性耐药的可能性，确定临床和分子特征似乎至关重要，这可以让临床医生选择合适的患者进行 177Lu-PSMA 治疗。这一领域迫切需要基于生物标志物的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment reviews 医学-肿瘤学

CiteScore

21.40

自引率

0.80%

发文量

109

审稿时长

13 days

期刊介绍： Cancer Treatment Reviews Journal Overview: International journal focused on developments in cancer treatment research Publishes state-of-the-art, authoritative reviews to keep clinicians and researchers informed Regular Sections in Each Issue: Comments on Controversy Tumor Reviews Anti-tumor Treatments New Drugs Complications of Treatment General and Supportive Care Laboratory/Clinic Interface Submission and Editorial System: Online submission and editorial system for Cancer Treatment Reviews